Table 1.
Baseline patient and disease characteristics.
| Characteristic n (%) | −100% to <− 60% n=283 (10%) | −60% to <− 30% n=547 (20%) | −30% to <0% n=1155 (42%) | 0% to <+20% n=390 (14%) | ≥ +20% n=156 (6%) | No Post- Baseline Imaging n=218 (8%) | Total Cohort n=2749 (100%) |
|---|---|---|---|---|---|---|---|
|
| |||||||
| Age at initiation of therapy | |||||||
| < 65 years | 196 (69%) | 345 (63%) | 762 (66%) | 271 (69%) | 112 (72%) | 142 (65%) | 1828 (66%) |
| ≥ 65 years | 87 (31%) | 202 (37%) | 393 (34%) | 119 (31%) | 44 (28%) | 76 (35%) | 921 (34%) |
|
| |||||||
| Sex | |||||||
| Male | 202 (71%) | 389 (71%) | 844 (73%) | 248 (64%) | 110 (71%) | 151 (69%) | 1944 (71%) |
| Female | 81 (29%) | 158 (29%) | 311 (27%) | 142 (36%) | 46 (29%) | 67 (31%) | 805 (29%) |
|
| |||||||
| Race | |||||||
| White | 258 (91%) | 436 (80%) | 968 (84%) | 336 (86%) | 135 (87%) | 178 (82%) | 2311 (84%) |
| Other | 25 (9%) | 111 (20%) | 187 (16%) | 54 (14%) | 21 (13%) | 40 (18%) | 438 (16%) |
|
| |||||||
| ECOG Performance Status | |||||||
| 0 | 169 (60%) | 319 (58%) | 537 (47%) | 153 (39%) | 63 (40%) | 41 (19%) | 1282 (47%) |
| 1 | 106 (37%) | 222 (42%) | 594 (51%) | 223 (57%) | 91 (58%) | 151 (69%) | 1387 (50%) |
| 2 | 3 (1%) | 4 (1%) | 15 (1%) | 11 (3%) | 0 (0%) | 25 (12%) | 58 (2%) |
| Unknown | 5 (2%) | 2 (<1%) | 3 (1%) | 3 (1%) | 2 (1%) | 1 (<1%) | 22 (1%) |
|
| |||||||
| Pathology | |||||||
| Clear cell | 255 (90%) | 493 (90%) | 1042 (90%) | 344 (88%) | 135 (87%) | 181 (83%) | 2450 (89%) |
| Non-clear cell | 18 (6%) | 26 (5%) | 51 (4%) | 26 (7%) | 10 (6%) | 9 (4%) | 140 (5%) |
| Unknown | 10 (4%) | 28 (5%) | 62 (5%) | 20 (5%) | 11 (7%) | 28 (13%) | 159 (6%) |
|
| |||||||
| Baseline metastatic site | |||||||
| Lung | 223 (79%) | 421 (77%) | 893 (77%) | 293 (75%) | 122 (78%) | 172 (79%) | 2124 (77%) |
| Bone | 61 (22%) | 129 (24%) | 336 (29%) | 126 (32%) | 48 (31%) | 81 (37%) | 781 (28%) |
| Liver | 64 (23%) | 118 (22%) | 314 (27%) | 129 (33%) | 62 (40%) | 79 (36%) | 766 (28%) |
| Othera | 183 (65%) | 423 (77%) | 963 (83%) | 337 (86%) | 126 (81%) | 184 (84%) | 2216 (81%) |
|
| |||||||
| Previous nephrectomy | |||||||
| Yes | 270 (95%) | 490 (90%) | 938 (81%) | 308 (79%) | 146 (94%) | 145 (64%) | 2297 (84%) |
| No | 12 (4%) | 26 (5%) | 121 (11%) | 45 (12%) | 3 (2%) | 23 (11%) | 248 (9%) |
| Unknown | 1 (1%) | 28 (5%) | 96 (8 %) | 37 (9%) | 7 (4%) | 50 (23%) | 204 (7%) |
|
| |||||||
| Prior type of therapy | |||||||
| Any prior therapy | 131 (46%) | 268 (49%) | 546 (47%) | 175 (45%) | 68 (44%) | 81 (37%) | 1269 (46%) |
| Cytokine therapy | 62 (22%) | 162 (30%) | 250 (22%) | 55 (14%) | 17 (11%) | 25 (12%) | 571 (21%) |
| Targeted therapy | 15 (5%) | 55 (10%) | 232 (20%) | 100 (26%) | 44 (28%) | 36 (17%) | 482 (18%) |
|
| |||||||
| MSKCC risk group | |||||||
| Favorable | 80 (28%) | 166 (30%) | 250 (22%) | 54 (14%) | 22 (14%) | 13 (6%) | 585 (21%) |
| Intermediate | 135 (48%) | 226 (41%) | 460 (40%) | 165 (42%) | 61 (39%) | 57 (26%) | 1104 (40%) |
| Poor | 41 (14%) | 91 (17%) | 330 (29%) | 134 (34%) | 61 (39%) | 119 (55%) | 776 (28%) |
| Unknown | 27 (10%) | 64 (12%) | 115 (10%) | 37 (10%) | 12 (8%) | 29 (13%) | 284 (10%) |
a
Other is defined as any other metastases excluding lung, bone and liver.
ECOG = Eastern Cooperative Oncology Group, MSKCC = Memorial Sloan-Kettering Cancer Center.